News

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company...

The Orthobiologic Institute and ZetrOZ Systems Launch 2024 Clinical Education Program on Non-Opioid and Non-Surgical Soft-Tissue Regenerative Techniques for Clinicians

Clinical education director Dr. Rajiv Mallipudi will present on sam® research and treatment protocols in a program for members of...

error: Content is protected !!